Cassava Sciences Stock Upgraded to 'Hold' by Wall Street Zen

Weiss Ratings maintains 'sell' rating on the biopharmaceutical company's shares.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen has upgraded its rating on Cassava Sciences (NASDAQ:SAVA) shares from 'sell' to 'hold', while Weiss Ratings has reiterated its 'sell' rating on the stock. Cassava Sciences is a clinical-stage biopharmaceutical company focused on developing novel therapies and diagnostics for Alzheimer's disease and related neurodegenerative disorders.

Why it matters

The mixed analyst ratings on Cassava Sciences' stock reflect the ongoing challenges and uncertainties facing the company's drug development efforts for Alzheimer's treatments. As a clinical-stage biopharma, Cassava's future performance will depend heavily on the success or failure of its lead drug candidate, simufilam.

The details

Wall Street Zen upgraded Cassava Sciences' stock from a 'sell' rating to a 'hold' rating in a report issued on Sunday. Separately, Weiss Ratings reiterated its 'sell (e+)' rating on Cassava shares in a report on Friday, December 26th. The company now has one 'hold' rating and one 'sell' rating from analysts. Several institutional investors, including Marshall Wace LLP, Jacobs Levy Equity Management, and Goldman Sachs, have recently bought and sold Cassava Sciences shares.

  • Wall Street Zen upgraded Cassava Sciences' stock on Sunday, March 9, 2026.
  • Weiss Ratings reiterated its 'sell' rating on Cassava Sciences on Friday, December 26th.

The players

Wall Street Zen

A financial research and analysis firm that upgraded Cassava Sciences' stock to a 'hold' rating.

Weiss Ratings

A financial research firm that reiterated its 'sell' rating on Cassava Sciences' stock.

Cassava Sciences, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies and diagnostics for Alzheimer's disease and related neurodegenerative disorders.

Marshall Wace LLP

An institutional investor that significantly increased its position in Cassava Sciences in the third quarter.

Jacobs Levy Equity Management

An institutional investor that purchased a new stake in Cassava Sciences.

Goldman Sachs Group Inc.

An institutional investor that grew its position in Cassava Sciences by 77.9% in the first quarter.

Got photos? Submit your photos here. ›

The takeaway

The mixed analyst ratings on Cassava Sciences' stock highlight the ongoing uncertainty surrounding the company's Alzheimer's drug development efforts. As a clinical-stage biopharma, Cassava's future performance will depend heavily on the success or failure of its lead drug candidate, simufilam.